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Background Rheumatoid arthritis is the most prevalent 
form of inflammatory arthritis. One of the key 
components for its multidimensional outcome is the 
disease activity, measured by DAS28-ESR. The 
physical, emotional, and social aspects of RA contribute 
to the quality of life, and SF-36 questionnaire can be 
used to measure it. This study aims to ascertain the 
correlation between the disease activity (DAS28-ESR) 
and the quality of life (SF-36) in RA patients. 
Method This study was an analytical, descriptive study 
with a cross sectional design that took primary data from 
RA patients undergoing treatment in Rheumatology 
Clinic of Hasan Sadikin Hospital from February to May 
2015. The patient’s data included sex, age, marital 
status, employment status, educational level, serostatus 
(RF and Anti-MCV), duration of diagnosis, total number 
of medications, total number of DMARD, DAS28-ESR 
scores, and SF-36 scores. The data was analysed with 
the Shapiro-Wilk normality test, followed by the Rank-
Spearman correlation analysis.  
Result There were 42 subjects, with an average age of 
41 ± 12. The ratio between females and males was 20:1, 
and the majority of subjects (73.8%) had a positive 
serostatus (RF and/or anti-MCV). The median score of 
DAS28-ESR was 4.3, while the median score for SF-36 
PCS being 39.8 and the median score for SF-36 MCS 
was 48.2. Based on the the Rank-Spearman analysis (CI 
of 95%), there was a correlation between DAS28-ESR 
score and SF-36 PCS score, with the correlation 
coefficient (r) of -0.577 (p < 0.001), also there was a 
correlation between DAS28-ESR score and SF-36 MCS 
score with r of -0.368 (p = 0.008).  
Conclusion There was a strong negative 
correlation between disease activity and physical 
component of quality of life, and a moderate 
negative correlation between disease activity and 
mental component of quality of life, and the two 
correlations were statistically significant.  
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Rheumatoid arthritis (RA) is the most prevalent 
form of inflammatory arthritis, with a prevalence of 
0.5 – 1% around the world.1,2 This disease can 
 
 
occur at any age, but the patients most affected are 
those in the third to sixth decade of their lives, 
which is a productive period of age.3 Data from 
Indonesia Basic Health Research (2007) and 
National Economic Social Survey (2007) showed 
that the prevalence in Indonesia was around 0.1%.4 
Even though this degree of prevalence is 
considered low, this disease is associated with 
many extra-articular and systemic complications 
that can lead to pain and disability as well as 
emotional, social, and economic problems.5 The 
mortality rate of the patients is also higher than that 
of the general population.6  
The outcome in quality of life is considered to be 
a more important aspect in the management of RA,14 
as the physical, emotional, and social aspects of RA 
contribute to the patients’ low quality of life.5 Based 
on a systematic review by Karimi et al. (2013), one of 
the factors that affects the quality of life is disease 
activity.15 A study result by Lu et al. (2008) showed a 
moderate-strong correlation between disease activity 
and the physical and mental components of quality of 
life.16 A different result occurred in a study by Kojima 
et al. (2008), where the correlation was only weak-
moderate, and the disease activity was independent 
from psychosocial factors, and did not reflect the 
physical and mental components of quality of life in 
RA patients.17 Another study by Radner et al. (2014) 
showed that disease activity only significantly 
correlated with the physical component of quality of 
life, not the mental component of quality of life.9  
There are several methods to assess quality of 
life, and the easiest and cheapest is a self-
administered questionnaire by the patients.18 The 
Short Form 36-item Health Survey Questionnaire 
(SF-36) is an example of a generic questionnaire 
most often used to evaluate quality of life as a 
subjective perception of psychological and physical 
limitations caused by the musculoskeletal diseases, 
and studies have supported its validity for use with 
RA patients.14,19  
This study aims to ascertain the correlation 
between disease activity measured by DAS28-ESR 
and physical and mental components of quality of 
life measured by SF-36 in RA patients. 
 
 




This study was an analytical descriptive study with a cross 
sectional design that took primary data from RA patients who 
were underwent treatment in Rheumatology Clinic of dr. Hasan 
Sadikin Hospital in Bandung, from February to May 2015. 
Sampling was done using consecutive sampling method.  
The inclusion criteria were all patients who fulfilled the 2010 
American College of Rheumatology/ European League Against 
Rheumatism (ACR/EULAR) criteria for rheumatoid arthritis, 
aged above 14 years old, can read and write, and no verbal 
communication impairment. All participants gave their consent 
to be enrolled in this study and the study protocol had been 
approved by the appropriate local ethical board. The exclusion 
criteria were patients with other diseases manifesting in joints and 
bone (osteoartritis, psoriatic arthritis, reactive arthritis, 
ankylosing spondilitis, fibromyalgia, gout arthritis, septic 
arthritis, and fractures), patients with infections, malignancies, 
and cardiovascular diseases, and patients with pain originating 
from areas other than joints. 
 
Assessment 
Study subjects would went through history taking, physical 
examinations, blood tests, and questionnaire-filling. The 
history taking was done to collect demographic characteristics 
included age, sex, profession, education level, and marital 
status. While clinical characteristics collected include the 
length of time since RA diagnosis, medications taken for the 
disease, and patients’ global assessment to calculate DAS28-
ESR score. The medications for RA referred to this study 
included glucocorticoid and DMARD (methotrexate, 
leflunomide, cyclosporine, etanercept, and infliximab), based 
on a systematic review by Blumenauer et al. (2003) about 
DMARD medications in RA patients.20 The physical 
examination was done to collect data on the number of 
swollen and tender joints which were needed to calculate 
DAS28-ESR score. The blood test was done to collect the data 
on patients’ serostatus (RF and anti-MCV), and ESR to 
calculate DAS28-ESR score. Then, the patients were asked to 
fill in the questionnaires to evaluate their quality of life.  
The DAS28-ESR score was calculated with a specific 
calculator downloaded from the internet, while the serostatus test 
(RF and anti-MCV) was done using the Rheumachec rapid test 
(Orgentec Diagnostika GmbH, Mainz, Germany), and the quality 
of life was evaluated using SF-36 questionnaires. 
 
Statistical Analysis 
Univariate analysis aimed to describe the characteristics of 
study subjects included age, sex, serostatus (RF and anti-MCV), 
SF-36 scores, DAS28-ESR scores, length of time since RA 
diagnosis, and number of medications taken for RA, which were 
presented in number and percentage for categorical data, and 
mean, standard of deviation, median, minimum and maximum for 
numerical data. To answer the hypothesis about the correlation 
between disease activity (DAS28-ESR score) and quality of life 
(SF-36 scores) in RA patients, we used the Rank Spearman 
correlation analysis. The data analysis was done using the 
Statistical Product and Service Solution 
 
 
(SPSS) for Windows version 18.0 program on the confidence 




The number of RA patients who went to Rheumatology Clinic 
in dr. Hasan Sadikin Hospital Bandung from January 2014 to 
June 2015 was 194 patients, consisting of 171 female patients 
and 23 male patients. This study was done over 4 months, from 
February to May 2015. There were 42 patients who fulfilled 
the inclusion criteria and did not fulfill the exclusion criteria. 
The baseline characteristics for study subjects are shown in 
Table 1 below. The Shapiro-Wilk test was used to test data 
normality of each characteristic. 
 




p value of  




    
     
Sex     
Male (%) 2 (4.8)   
Female (%) 40 (95.2)   
Age (year)     
(mean ± SD) 41±12 0.088 Normal 
Marital Status     
Married (%) 32 (76.2)   
Widowed (%) 3 (7.1)   
Not married (%) 7 (16.7)   
Profession     
Housewife (%) 24 (57.1)   
Employee of private sector (%) 5 (11.9)   
Farmer (%) 1 (2.4)   
Student (%) 3 (7.14)   
Government employee (%) 8 (19.1)   
Not working (%) 1 (2.4)   
Education Level     
Elementary school (%) 4 (9.5)   
Junior high school (%) 7 (16.7)   
Senior high school (%) 20 (47.6)   
Academy (%) 4 (9.5)   
University (%) 7 (16.7)   
Serostatus     
RF (+) and Anti-MCV (+) 5 (11.9)   
RF (+) and Anti-MCV (-) 25 (59.5)   
RF (-) and Anti-MCV (+) 1 (2.4)   
RF (-) and Anti-MCV (-) 11 (26.2)   
Length of time since RA diagnosis     
(month)     
(Median (range)) 24 (1 – 216) <0.001 Not Normal 
Number of RA medication     
(Median (range)) 3(1–4) <0.001 Not Normal 
Number of DMARD     
(Median (range)) 2(1–3) <0.001 Not Normal 
      
*Normality test using Shapiro-Wilk test, data has a normal 
distribution if p>0.05 
 
Most of the study subjects were female, by a ratio of 20:1 
between the number of females and males. The youngest subject 
was 18 and the oldest was 61. The fifth decade was the largest 
group of the study subjects (31%). The next largest groups were 
the third and the fourth decades, each being of 19%. The number 
of study subjects with positive serostatus 
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(positive RF and/or anti-MCV) was more than the study 
subjects with negative serostatus (negative RF and anti-
MCV), was 31 subjects (73.8%). There were 8 study subjects 
(19%) which had the length of time since RA diagnosis was < 
6 months, and 34 study subjects (81%) which had the length 
of time since RA diagnosis ≥ 6 months. There were 5 study 
subjects (11.9%) who did not get glucocorticoid. The data for 
DAS28-ESR scores and SF-36 scores can be seen in Table 2 
below. 
 






n=42   
  
DAS28-ESR Score(Median (range)) 4.3 (2.2 – 6.5) 
SF-36 (PCS) Score(Median (range)) 39.8 (26.4 – 53.1) 
SF-36 (MCS) Score(Median (range)) 48.2 (30.1 – 61.5) 
   
 
The results of this study also showed that disease activity in 
most study subjects (67%) were moderate, followed by high 
disease activity in 8 patients (19%), and low disease activity in 6 
patients (14%). Before analysing the correlation between disease 
activity score (DAS28-ESR) and physical component of quality 
of life (SF-36 PCS), a plot was made based on the distribution of 
data from these two variables, as seen in Figure 1 below. Before 
analysing the correlation between disease activity score (DAS28-
ESR) and mental component of quality of life (SF-36 MCS), a 
plot was made based on the distribution of data from these two 
variables, as seen in Figure 2 below. To find the correlation value 
between DAS28-ESR variable with the physical and mental 
components of quality of life, the Rank-Spearman correlation 
analysis was carried out. The results from the Rank-Spearmen 
correlation analysis showing the correlation coefficients between 
the DAS28-ESR score and physical and mental components of 
quality of life are shown in Table 3 below. 
 
Figure 1. Scatterplot of Correlation between 
DAS28-ESR Scores and SF-36 PCS Scores  
Original Article  
 
Figure 2. Scatterplot of Correlation between DAS28-























Table 3. Correlation Coefficients between Disease 
Activity (DAS28-ESR) and Quality of Life (SF-36) 
 
 
  Quality of Life (Skor SF-36) 
    
  PCS MCS 
    
DAS28-ESR 
r
s -0.577 -0.368 
 p value* <0.001 0.008 
    
 
*Note: Analysis using Rank-Spearman correlation, significant if p<0,05 
 
Based on the result of correlation analysis in Table 3, at 
95% confidence interval, there was a strong negative 
correlation between DAS28-ESR score and SF-36 PCS score 
(r = -0.577; p < 0.001) and a moderate negative correlation 
between DAS28-ESR score and SF-36 MCS score (r = -0.368; 
p = 0.008). These results showed that the higher the DAS28-
ESR, the lower the SF-36 PCS and MCS scores, and both 
correlations were statistically significant. 
 
Discussion 
The exact cause of higher RA prevalence in females is 
unknown, but genetic factors (X-linked) and female sex 
hormones, especially during peri-menopausal period, might 
play a role.21,22 From literature, the ratio between the number 
of female and male patients is usually around 3 : 1, such as the 
result from a study by Chen et al. (2007) in Taiwan.13,23 Larger 
ratios were found in other studies, such as 4.5:1 in a study by 
Lu et al. (2008) in Taiwan, and 5 : 1 in a study by Benitha et 
al. (2007) in South Africa.16,24  
Regional variations in RA prevalence might be influenced by 
behavioral factors, climate, environmental exposure, diagnostic 
approach for RA, and genetic factors.25,26 The gender difference 
in RA is not limited only to prevalence, but also to clinical course 
and prognosis.27 Several differences are associated with 
differences in clinical presentation, which male patients more 
often seek medical treatment related to symptoms in spine, while 
female patients more often seek 
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medical treatment related to symptoms in peripheral joints (such 
as in RA).28 An international chort study (QUEST-RA) done by 
Sokka et al. (2009) showed higher disease activity and poorer 
physical function in female patients than male patients. Female 
patients experienced higher subjective disease activity and 
DAS28 than male patients.27 A study by Smedstad et al. (1995) 
showed that female gender was associated with a reduction in 
physical abilities.29 Female patients are less strong than male 
patients, which affects their functional status, so the same burden 
from musculoskeletal diseases will lead to a worse effect in 
female patients.27 In terms of seeking treatment, a study by Chung 
et al. (2006) showed that females were significantly associated 
with the tendency to seek medical attention for hand deformities 
in RA.30  
The mean age for study subjects was 41 ± 12 year old, with 
the largest age group those in the fifth decade. The result of 
our study was similar to most literature which stated the 
highest RA prevalence is in the fifth decade, which is the 
period of hormonal change in women.6,13,21 Similar results 
were also found in other studies, such as by Alishiri et al. 
(2011) in Iran.31 The most significant age groups were the 
third and fourth decade, each showing 19%, and our result was 
also similar to a study result in Australia, which found two 
peaks of RA prevalence, the third and fifth decade.3  
According to ACR, early-stage RA is defined as patients 
with a duration of disease < 6 months, while late-stage RA is 
defined as patients with a duration of disease ≥ 6 months.32 
From our study, the majority of patients (81%) who came to 
the clinic were late-stage patients.  
From EULAR recommendations, DMARD therapy should be 
started as early as possible and if the treatment target is not 
achieved with the first DMARD strategy, switch to another 
synthetic DMARD or an addition of biologic DMARD is 
recommended.33 The number of DMARDs combined can reach 
2─3 drugs.32 From IRA (Indonesian Rheumatology Association) 
recommendations, all RA patients should also get DMARDs as 
soon as possible, ideally within 3 months after the symptoms 
start. Patients with early-onset RA should get DMARDs 
combination therapy, and if it’s not possible, DMARD 
monotherapy with a rapid dose escalation until clinically 
effective dose is reached.34 From a systematic review by Schoels 
et al. (2010) on cost-effectivity of RA therapeutic options, the 
treatment strategy that aimed to maintain the physical function 
was cost-effective, even when it involved more expensive 
biologic DMARDs.35 Even though there is a significant increase 
in cost, these drugs can lower the disease activity significantly 
and decrease the joint damage.9 From our study, the median 
number of DMARDs given to the study subjects was still not 
maximum, with the median of duration diagnosed with RA 
relatively long (24 months). The number of synthetic DMARDs 
taken by most study subjects was not the maximum number, and 
none of the patients were ever administered biologic DMARDs. 
 
Based on previous studies, RF can be detected in 60 – 80% 
RA patients.36,37 A similar result was found in our study, which 
RF was positive in 30 study subjects (71.4%). While for anti-
MCV, the prevalence of RA patient in population is still 
unknown and in this study we only found positive anti- 
 
 
MCV in 6 study subjects (14.3%). The difference in ACPA 
prevalences across studies can be caused by factors such as 
genetic (SE HLA-DRβ1), behavior such as smoking, test method, 
the duration of the disease, and therapy.38,39 Even though the SE 
alleles are the most noted genetic risk factor for ACPA positivity, 
the new genetic analysis have detected non-SE-HLA and non-
HLA alleles as predisposition for ACPA, such as a few SNP 
(single nucleotide polymorphism) of PADI4 in Asian 
populations.6,25,40 Another important risk factor is smoking. Based 
on study conducted by Klareskog et al. (2002) in Sweden, 
smoking was associated as a risk factor for RA with positive 
ACPA only in patients with positive SE.41 The level of ACPA was 
also influenced by therapy, as found in the study by Ally et al. 
(2015), which synthetic DMARD use was associated with a 
significant decrease in the ACPA level.39 In our study, we didn’t 
carry out a genotype test, the history of smoking in the subjects 
was unknown, and the ACPA test was done with a qualitative 
method using POCT.  
The study results showed that the disease activity in most 
study subjects was moderate, followed by some subjects had high 
disease activity, and the other subjects had low disease activity. 
This result showed that one of the targets in RA management, 
which had a low disease activity or remission, was still not 
achieved in most subjects. A similar result was also found in a 
study by Haroon et al. (2007) in India, with a mean DAS28 score 
of 4.43.42 One of the factors is the “treat to target” strategy that is 
still not fully implemented in our clinic. It might be caused by 
several factors such as doctors who haven’t given RA therapy 
according to EULAR recommendatios, or factors related to 
DMARDs use, such as their availability and sustainability. A 
study result from tREACH (Treatment in the Rotterdam Early 
Arthritis CoHort), which was presented at the annual congress of 
EULAR 2015 showed that initial therapy using DMARDs 
combination significantly improved disease activity and fuctional 
capacity in early-stage RA, compared to DMARD monotherapy.43 
In our clinic, the DMARDs haven’t been optimally used, where 
the number and dose of synthetic DMRADs taken by most 
subjects were probably not of the maximum limit, and these study 
subjects were never administered biologic DMARDs. Patients’ 
compliance to DMARD therapy also affects their disease activity. 
A study by Pascual-Ramos et al. (2009) showed that patients who 
were compliant had a lower DAS28 score and greater 
improvement in the score during follow-up, and also achieved 
more long-lasting remission.44 The DAS28 score consists of 
clinical, biochemical, and patient-reported outcomes, so 
psychological factor can influence the subjective component 
reported by patients.45 Based on a study by Kojima et al. (2009), 
the disease activity components were also associated with 
symptoms felt by patients and patients’ physical function.17 
Examples of these symptoms are the duration and severity of 
morning stiffness and the intensity of pain upon waking up in the 
morning.46 From clinical trials, other factors such as structural 
damage that can be assessed radiologically is also associated with 
disease activity.47 In our study, we didn’t take data on patients’ 
compliance, psychological states, current symptoms, physical 
function, or radiological damage. 
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From our study, the median score for physical component 
of quality of life is lower than the median score for mental 
component of quality of life. A similar result was found in a 
study by Alishiri et al. (2011) and Salaffi et al. (2009).19,31  
Based on the Rank-Spearman correlation analysis, in our 
study we found a strong negative correlation between disease 
activity and physical component of quality of life, and a moderate 
correlation between disease activity and mental component of 
quality of life. These results showed that the correlation between 
disease activity with the quality of life is stronger in the physical 
component, compared to the mental component. Similar results 
were also found in studies by Lu et al. in Taiwan and Alishiri et 
al. in Iran.16,31 Different results were found in a study by Kwan et 
al. (2014) and Kojima et al. (2009) which disease activity was not 
significantly correlated with the quality of life and could not 
reflect the physical and mental components of the quality of life 
in RA patients.17,48 In our study, disease activity showed a 
moderate – strong correlation with quality of life, and this might 
be caused by non-disease-related aspects included in the 
questionnaires for the quality of life, which are not measured by 
DAS28 score. The results from previous studies by Van der 
Heijde et al. (1992) and Chikanza et al. (1994) showed that 
variables related to disease were strong determinants for physical 
disability, but not for mental health.49,50 The mechanism for the 
correlation between DAS28 score and physical component can be 
caused by the close relationship between disease activity and the 
extent of inflammation and joint damage, including the degree of 
clinical disease activity, pain, stiffness, and joint swelling.31  
The difference in correlation significancies between our study 
and other studies might be caused by differences in the study 
design, sample size, case definition and selection of subjects, the 
instruments used in the studies, data presentation, and even 
culture and language. Because of various limitations, in our study 
we couldn’t examine factors that theoretically can affect quality 
of life, such as patients’ functional capacity, disease perception, 
degree of fatigue, radiological damage, presence of 
comorbidities, potential side effects from drugs, coping 




In this study we found a strong negative correlation between 
disease activity and physical component of quality of life, and 
a moderate negative correlation between disease activity and 
mental component of quality of life. Therefore, the higher the 
disease activity, the lower the physical and mental 
components of quality of life.  
The majority of study subjects were female (95.2%), in their 
fifth decade of age (31%),and had a positive serostatus (RF and/or 
anti-MCV) (73.8%). The median score for disease activity was 
4.30 (range 2.2 – 6.5), and most study subjects (67%) had a 
moderate disease activity, followed by a high disease activity 
(19%), and a low disease activity in 6 study subjects (14%). The 
median score for physical component was lower than the median 
score for mental component of quality of life, that was 39.8 (range 
26.4 – 53.1) for physical component and 48.2 (range 30.1 – 61.5) 
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